Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Precision medicine in psychiatry: biomarkers to the forefront

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N, et al. Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. Mol Psychiatry. 2015;20:1266–85.

    CAS  Article  Google Scholar 

  2. Rangaraju S, Levey DF, Nho K, Jain N, Andrews KD, Le-Niculescu H, et al. Mood, stress and longevity: convergence on ANK3. Mol Psychiatry. 2016;21:1037–49.

    CAS  Article  Google Scholar 

  3. Niculescu AB, Le-Niculescu H, Levey DF, Roseberry K, Soe KC, Rogers J, et al. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Mol Psychiatry. 2019;24:501–22.

    CAS  Article  Google Scholar 

  4. Le-Niculescu H, Roseberry K, Levey DF, Rogers J, Kosary K, Prabha S, et al. Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs. Mol Psychiatry. 2020;25:918–38.

    CAS  Article  Google Scholar 

  5. Niculescu AB, Le-Niculescu H, Roseberry K, Wang S, Hart J, Kaur A, et al. Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2020;25:1651–72.

    CAS  Article  Google Scholar 

  6. Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, et al. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01061-w.

Download references

Acknowledgements

We would like to acknowledge our gratitude for the work and results of the many other groups, cited in our papers, who have conducted and published studies (clinical, genetic, and biological) in psychiatry. Combining their work with ours makes a convergent approach possible. We would like to thank members of the Niculescu Lab for the excellent work over the years. We also would particularly like to thank the subjects in our studies and their families. Without their contribution, such work to advance the objective understanding and treatment of psychiatric disorders would not be possible.

Funding

This work was supported by NIH grants (1DP2OD007363 and R01MH117431) and a VA Merit Award (2I01CX000139) to ABN. ABN is listed as inventor on patent applications filed by Indiana University, and is a co-founder of MindX Sciences. HLN has no disclosures

Author information

Authors and Affiliations

Authors

Contributions

ABN conceived and wrote the manuscript. HLN provided comments and suggestions.

Corresponding author

Correspondence to Alexander B. Niculescu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Niculescu, A.B., Le-Niculescu, H. Precision medicine in psychiatry: biomarkers to the forefront. Neuropsychopharmacol. 47, 422–423 (2022). https://doi.org/10.1038/s41386-021-01183-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41386-021-01183-3

Search

Quick links